Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2
暂无分享,去创建一个
M. Diamond | D. Douek | M. Kiso | Shinji Watanabe | Y. Kawaoka | M. Saito | P. Halfmann | Sucheta Godbole | M. Imai | Tadaki Suzuki | H. Hasegawa | Mutsumi Ito | A. Yasuhara | S. Yamayoshi | Ryuta Uraki | N. Ohmagari | M. Koga | E. Adachi | T. Tsutsumi | H. Yotsuyanagi | Y. Sakai | S. Hattori | Zhongde Wang | K. Mitamura | Tadashi Maemura | Rong Li | K. Maeda | S. Fujisaki | S. Loeber | K. Iwatsuki-Horimoto | E. Takashita | S. Ozono | H. Ueki | Y. Furusawa | M. Hagihara | Zhenlu Chong | Deanna P Larson | M. Ujie | Shohei Matsubara | M. Okuda | J. Murakami | C. Duong | S. Iida | R. Wright | Yanan Liu | M. Kuroda | Shinya Yamamoto | Tetsuro Sato | Masayuki Hojo | H. Mitsuya | T. Sato | R. Uraki | Seiichiro Fujisaki | Maki Kiso
[1] M. Baniecki,et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.
[2] J. Zahradník,et al. Virological characteristics of SARS-CoV-2 BA.2 variant , 2022, bioRxiv.
[3] Liyuan Liu,et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages , 2022, Nature.
[4] Graham W. Taylor,et al. Post-peak dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022 , 2022, medRxiv.
[5] A. Kaneda,et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant , 2022, Nature.
[6] K. Spiess,et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households , 2022, medRxiv.
[7] Y. Orba,et al. Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19 , 2022, bioRxiv.
[8] Shinji Watanabe,et al. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant , 2022, The New England journal of medicine.
[9] Larissa B. Thackray,et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters , 2022, Nature.
[10] L. Poon,et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination , 2022, Nature Medicine.
[11] D. von Laer,et al. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons , 2022, The New England journal of medicine.
[12] Alexandra Flemming. Omicron, the great escape artist , 2022, Nature Reviews Immunology.
[13] K. To,et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron , 2021, Nature.
[14] M. Kiso,et al. Therapeutic e cacy of antibodies and antivirals against a SARS-CoV-2 Omicron variant , 2022 .
[15] Jordan J. Clark,et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron , 2021, Nature.
[16] R. Sarkar,et al. Mutational and phylogenetic analyses of the two lineages of the Omicron variant , 2021, Journal of medical virology.
[17] P. Maes,et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.
[18] A. Telenti,et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift , 2021, Nature.
[19] S. Weaver,et al. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection , 2021, bioRxiv.
[20] Fei Shao,et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.
[21] Liyuan Liu,et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.
[22] P. Schommers,et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant , 2021, Nature Medicine.
[23] Heidi Ledford,et al. How bad is Omicron? What scientists know so far , 2021, Nature.
[24] G. Whittaker,et al. Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike , 2021, iScience.
[25] Y. Kawaoka,et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation , 2021, Nature.
[26] Vineet D. Menachery,et al. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission , 2021, Nature.
[27] S. Elbashir,et al. mRNA-1273 Protects against SARS-CoV-2 Beta Infection in Nonhuman Primates , 2021, Nature Immunology.
[28] K. Gajiwala,et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 , 2021, Science.
[29] Y. Terada,et al. Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovines , 2021, bioRxiv.
[30] D. O’Connor,et al. Characterization of a new SARS-CoV-2 variant that emerged in Brazil , 2021, Proceedings of the National Academy of Sciences.
[31] Vineet D. Menachery,et al. Mouse Adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge , 2021, bioRxiv.
[32] D. Fremont,et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies , 2021, Nature Medicine.
[33] Lisa E. Gralinski,et al. SARS-CoV-2 Infection is Effectively Treated and Prevented by EIDD-2801 , 2021, Nature.
[34] Y. Kawaoka,et al. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months , 2021, EClinicalMedicine.
[35] Vineet D. Menachery,et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera , 2021, bioRxiv.
[36] Lisa E. Gralinski,et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo , 2020, Science.
[37] Lisa E. Gralinski,et al. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice , 2020, Cell.
[38] Tsuyoshi Sekizuka,et al. Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR , 2020, PloS one.
[39] Lisa E. Gralinski,et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures , 2020, Nature.
[40] Shamus P. Keeler,et al. SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function , 2020, Nature Immunology.
[41] Tokiko Watanabe,et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development , 2020, Proceedings of the National Academy of Sciences.
[42] K. To,et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] Jonathan H. Chung,et al. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA , 2020, Journal of thoracic imaging.
[44] Fumihiro Kato,et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells , 2020, Proceedings of the National Academy of Sciences.
[45] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[46] Z. Fayad,et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV) , 2020, Radiology.
[47] M. Kiso,et al. Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus , 2019, Nature Microbiology.
[48] David K. Meyerholz,et al. Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus , 2006, Journal of Virology.